Synergy Pharmaceuticals Inc news

   Watch this stock
Showing stories 1 - 10 of about 87   

Articles published

SGYP 3.05 +0.06 (2.01%)
price chart
Synergy Pharmaceuticals Initiates First Phase 3 Clinical Trial of Plecanatide ...
NEW YORK--(BUSINESS WIRE)--Synergy Pharmaceuticals Inc. (NASDAQ:SGYP) announced today the initiation of the first of two planned pivotal phase 3 clinical trials evaluating the safety and efficacy of 3.0 and 6.0 mg plecanatide, once-daily oral tablets, ...
Synergy Pharmaceuticals, Inc. (SGYP) Surges: Stock Rises 10%
Synergy Pharmaceuticals, Inc. (SGYP - Snapshot Report) was a big mover last session, as the company saw its shares rise 10% on the day.
Related articles »  
Synergy Pharmaceuticals, Inc. (SGYP) Surges: Stock Rises 10% - Tale of the Tape
was a big mover last session, as the company saw its shares rise 10% on the day. The move came on solid volume too with far more shares changing hands than in a normal session This continues the recent uptrend for the company as the stock is now up ...
Related articles »  
Synergy Pharmaceuticals Inc (SGYP): Synergy Pharmaceuticals' Upcoming Trial ...
With multiple 2014 catalysts approaching, investor interest should remain strong for Synergy Pharmaceuticals. With positive data thus far, additional promising data could be strong share price movers for the company as additional indications are ...
Synergy Pharma Progresses with Plecanatide  Zacks.com
Related articles »  
Synergy Pharmaceuticals Inc. Announces Pricing of Private Offering of $175 ...
NEW YORK--(BUSINESS WIRE)--Synergy Pharmaceuticals Inc. (Nasdaq:SGYP), a developer of new drugs to treat gastrointestinal (GI) disorders and diseases, today announced the pricing of its private offering of $175 million aggregate principal amount of ...
Related articles »  
Synergy Pharmaceuticals Inc (SGYP): BioPharma Catalyst And Investment Pick ...
Synergy's biochemists believe that this is the reason for Plecanatide's low incidence of diarrhea as a side effect compared to approved IBS-C products Amitiza by Sucampo (SCMP) and Linzess by Ironwood Pharmaceuticals (IRWD). Diarrhea is the most ...
Synergy Pharmaceuticals Inc (SGYP), Proteon Therapeutics Inc (PRTO): James ...
Synergy Pharmaceuticals Inc (NASDAQ:SGYP) and Proteon Therapeutics Inc (NASDAQ:PRTO) are in the spotlight as James E. Flynn's Deerfield Management and Peter Kolchinsky's RA Capital Management started new stakes in them lately.
Cantor Fitzgerald Reaffirms Buy Rating for Synergy Pharmaceuticals (SGYP)  sleekmoney
Related articles »  
Synergy Pharmaceuticals Inc. Announces Issuance of $200 Million of 7.50 ...
NEW YORK--(BUSINESS WIRE)--Synergy Pharmaceuticals Inc. (Nasdaq:SGYP), a developer of new drugs to treat gastrointestinal (GI) disorders and diseases, today announced the closing of its previously announced private offering of $200 million ...
Related articles »  
Synergy Pharmaceuticals Inc. Announces Full Exercise of Over-Allotment Option
NEW YORK--(BUSINESS WIRE)--Synergy Pharmaceuticals Inc. (Nasdaq:SGYP), a developer of new drugs to treat gastrointestinal (GI) disorders and diseases, today announced the full exercise of the over-allotment option granted to the initial purchasers to ...
Synergy Pharmaceuticals Rating Reiterated by Cantor Fitzgerald (SGYP)  Intercooler
Related articles »  
Synergy Pharmaceuticals Inc. Announces Private Offering of Convertible Senior ...
NEW YORK--(BUSINESS WIRE)--Synergy Pharmaceuticals Inc. (Nasdaq:SGYP) (the �Company�), a developer of new drugs to treat gastrointestinal (GI) disorders and diseases, today announced that it is offering to sell up to $150 million principal amount of ...
Related articles »